- Home
- APVO vs GLTO Comparison
APVO vs GLTO Comparison
Compare APVO & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- GLTO
- Stock Information
- Founded
- APVO 2016
- GLTO 2011
- Country
- APVO United States
- GLTO Denmark
- Employees
- APVO N/A
- GLTO N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- GLTO Health Care
- Exchange
- APVO Nasdaq
- GLTO Nasdaq
- Market Cap
- APVO 4.1M
- GLTO 4.5M
- IPO Year
- APVO N/A
- GLTO 2020
- Fundamental
- Price
- APVO $3.06
- GLTO $3.75
- Analyst Decision
- APVO Strong Buy
- GLTO Buy
- Analyst Count
- APVO 1
- GLTO 1
- Target Price
- APVO $5,920.00
- GLTO $10.00
- AVG Volume (30 Days)
- APVO 191.0K
- GLTO 26.0K
- Earning Date
- APVO 08-07-2025
- GLTO 08-11-2025
- Dividend Yield
- APVO N/A
- GLTO N/A
- EPS Growth
- APVO N/A
- GLTO N/A
- EPS
- APVO N/A
- GLTO N/A
- Revenue
- APVO N/A
- GLTO N/A
- Revenue This Year
- APVO N/A
- GLTO N/A
- Revenue Next Year
- APVO N/A
- GLTO N/A
- P/E Ratio
- APVO N/A
- GLTO N/A
- Revenue Growth
- APVO N/A
- GLTO N/A
- 52 Week Low
- APVO $2.81
- GLTO $2.01
- 52 Week High
- APVO $381.10
- GLTO $15.13
- Technical
- Relative Strength Index (RSI)
- APVO 38.28
- GLTO 59.58
- Support Level
- APVO $3.01
- GLTO $3.40
- Resistance Level
- APVO $3.18
- GLTO $3.90
- Average True Range (ATR)
- APVO 0.16
- GLTO 0.33
- MACD
- APVO 0.19
- GLTO 0.01
- Stochastic Oscillator
- APVO 45.45
- GLTO 58.13
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.